阿戈美拉汀治疗抑郁症临床应用专家建议

2018-11-30 中国精神科相关专家小组 中国新药与临床杂志.2018,37(11):601-607.

抑郁症具有高患病率、高复发率和疾病负担重等特点, 经规范治疗, 仍有部分患者疗效欠佳或存在残留症状。阿戈美拉汀作为一种新的抗抑郁药, 其作用机制突破了传统单胺递质系统, 特异性激动褪黑素受体, 同时拮抗5- HT2C受体。由于其独特的作用机制, 阿戈美拉汀除了改善抑郁情绪, 还具有调节睡眠和生物节律、性功能影响少、耐受性好、不影响体重、撤药反应小等优势。因为阿戈美拉汀潜在肝功能损害的风险, 临床使

中文标题:

阿戈美拉汀治疗抑郁症临床应用专家建议

发布日期:

2018-11-30

简要介绍:

抑郁症具有高患病率、高复发率和疾病负担重等特点, 经规范治疗, 仍有部分患者疗效欠佳或存在残留症状。阿戈美拉汀作为一种新的抗抑郁药, 其作用机制突破了传统单胺递质系统, 特异性激动褪黑素受体, 同时拮抗5- HT2C受体。由于其独特的作用机制, 阿戈美拉汀除了改善抑郁情绪, 还具有调节睡眠和生物节律、性功能影响少、耐受性好、不影响体重、撤药反应小等优势。因为阿戈美拉汀潜在肝功能损害的风险, 临床使用中需定期监测肝功能, 注意与某些药物联用禁忌等问题。本文重点介绍国内外阿戈美拉汀临床应用中的循证证据、用药方法、安全性、临床应用特色、临床相关问题和处理等, 结合广大专家的用药经验, 为临床医生提供用药参考, 从而促进抑郁症患者治疗结局和预后的改善, 促进患者回归社会。 

拓展指南:抑郁相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=阿戈美拉汀治疗抑郁症临床应用专家建议)] GetToolGuiderByIdResponse(projectId=1, id=2a53f1c0016e30c8, title=阿戈美拉汀治疗抑郁症临床应用专家建议, enTitle=, guiderFrom=中国新药与临床杂志.2018,37(11):601-607., authorId=null, author=, summary=抑郁症具有高患病率、高复发率和疾病负担重等特点, 经规范治疗, 仍有部分患者疗效欠佳或存在残留症状。阿戈美拉汀作为一种新的抗抑郁药, 其作用机制突破了传统单胺递质系统, 特异性激动褪黑素受体, 同时拮抗5- HT2C受体。由于其独特的作用机制, 阿戈美拉汀除了改善抑郁情绪, 还具有调节睡眠和生物节律、性功能影响少、耐受性好、不影响体重、撤药反应小等优势。因为阿戈美拉汀潜在肝功能损害的风险, 临床使, cover=, journalId=null, articlesId=null, associationId=812, associationName=中国精神科相关专家小组, associationIntro=null, copyright=0, guiderPublishedTime=Fri Nov 30 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>抑郁症具有高患病率、高复发率和疾病负担重等特点, 经规范治疗, 仍有部分患者疗效欠佳或存在残留症状。阿戈美拉汀作为一种新的抗抑郁药, 其作用机制突破了传统单胺递质系统, 特异性激动褪黑素受体, 同时拮抗5- HT2C受体。由于其独特的作用机制, 阿戈美拉汀除了改善抑郁情绪, 还具有调节睡眠和生物节律、性功能影响少、耐受性好、不影响体重、撤药反应小等优势。因为阿戈美拉汀潜在肝功能损害的风险, 临床使用中需定期监测肝功能, 注意与某些药物联用禁忌等问题。本文重点介绍国内外阿戈美拉汀临床应用中的循证证据、用药方法、安全性、临床应用特色、临床相关问题和处理等, 结合广大专家的用药经验, 为临床医生提供用药参考, 从而促进抑郁症患者治疗结局和预后的改善, 促进患者回归社会。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>抑郁</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=680481c001638032" title="2018 NAMS/NNDC指南:围绝经期抑郁的评估和治疗" target=_blank>2018 NAMS/NNDC指南:围绝经期抑郁的评估和治疗</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=93e941c0016359e6" title="圣·约翰草提取物片治疗抑郁障碍专家共识" target=_blank>圣·约翰草提取物片治疗抑郁障碍专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=19d8b1c0015628c0" title="2018 AAP指南:基层医疗中青少年抑郁症的管理" target=_blank>2018 AAP指南:基层医疗中青少年抑郁症的管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=9f0081c00151362e" title="老年期抑郁障碍诊疗专家共识" target=_blank>老年期抑郁障碍诊疗专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=6992d1c001a89662" title="2017 佛罗里达最佳实践指南:成人抑郁症的药物治疗" target=_blank>2017 佛罗里达最佳实践指南:成人抑郁症的药物治疗</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E6%8A%91%E9%83%81" target=_blank>有关抑郁更多指南</a></ul>, tagList=[TagDto(tagId=13809, tagName=阿戈美拉汀), TagDto(tagId=228, tagName=抑郁症), TagDto(tagId=611, tagName=临床应用)], categoryList=[CategoryDto(categoryId=13, categoryName=精神心理科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=10814, appHits=377, showAppHits=2, pcHits=7171, showPcHits=4998, likes=205, shares=12, comments=4, approvalStatus=1, publishedTime=Sat Dec 08 11:42:29 CST 2018, publishedTimeString=2018-11-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sat Dec 08 11:42:29 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 10:40:28 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=阿戈美拉汀治疗抑郁症临床应用专家建议)])
阿戈美拉汀治疗抑郁症临床应用专家建议
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1184943, encodeId=78d911849430a, content=值得阅读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50ec5699921, createdName=ms3000001712111982, createdTime=Sun Jan 16 20:26:13 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901608, encodeId=c488901608b8, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210906/e141ddca670e4042bffbf47e00f8d2fd/b6517df71dfe42cb979aacdc454225cc.jpg, createdBy=0c532181739, createdName=12074e34m25(暂无昵称), createdTime=Mon Nov 23 23:25:39 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897548, encodeId=387e89e548dd, content=很好哦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201122/57c187a242b241d18d3c5e128f8a3a4e/bde57426d6b94920a3f4b30da3730a33.jpg, createdBy=c58e1700242, createdName=ahongyu, createdTime=Sat Nov 07 11:46:32 CST 2020, time=2020-11-07, status=1, ipAttribution=)]
    2022-01-16 ms3000001712111982

    值得阅读

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1184943, encodeId=78d911849430a, content=值得阅读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50ec5699921, createdName=ms3000001712111982, createdTime=Sun Jan 16 20:26:13 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901608, encodeId=c488901608b8, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210906/e141ddca670e4042bffbf47e00f8d2fd/b6517df71dfe42cb979aacdc454225cc.jpg, createdBy=0c532181739, createdName=12074e34m25(暂无昵称), createdTime=Mon Nov 23 23:25:39 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897548, encodeId=387e89e548dd, content=很好哦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201122/57c187a242b241d18d3c5e128f8a3a4e/bde57426d6b94920a3f4b30da3730a33.jpg, createdBy=c58e1700242, createdName=ahongyu, createdTime=Sat Nov 07 11:46:32 CST 2020, time=2020-11-07, status=1, ipAttribution=)]
    2020-11-23 12074e34m25(暂无昵称)

    好好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1184943, encodeId=78d911849430a, content=值得阅读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50ec5699921, createdName=ms3000001712111982, createdTime=Sun Jan 16 20:26:13 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901608, encodeId=c488901608b8, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210906/e141ddca670e4042bffbf47e00f8d2fd/b6517df71dfe42cb979aacdc454225cc.jpg, createdBy=0c532181739, createdName=12074e34m25(暂无昵称), createdTime=Mon Nov 23 23:25:39 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897548, encodeId=387e89e548dd, content=很好哦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201122/57c187a242b241d18d3c5e128f8a3a4e/bde57426d6b94920a3f4b30da3730a33.jpg, createdBy=c58e1700242, createdName=ahongyu, createdTime=Sat Nov 07 11:46:32 CST 2020, time=2020-11-07, status=1, ipAttribution=)]
    2020-11-07 ahongyu

    很好哦

    0